argenx SE (NASDAQ:ARGX - Free Report) - Stock analysts at Wedbush lifted their Q3 2024 earnings per share (EPS) estimates for shares of argenx in a research note issued on Tuesday, March 26th. Wedbush analyst D. Nierengarten now expects that the company will post earnings per share of ($1.01) for the quarter, up from their previous forecast of ($1.02). The consensus estimate for argenx's current full-year earnings is ($2.07) per share. Wedbush also issued estimates for argenx's Q4 2024 earnings at ($0.95) EPS, FY2024 earnings at ($3.81) EPS, FY2026 earnings at $13.45 EPS and FY2027 earnings at $33.82 EPS.
Other equities research analysts have also recently issued reports about the stock. Wells Fargo & Company upped their target price on shares of argenx from $472.00 to $478.00 and gave the company an "overweight" rating in a report on Tuesday, February 20th. William Blair lowered shares of argenx from an "outperform" rating to a "market perform" rating in a research report on Wednesday, December 20th. JMP Securities restated a "market outperform" rating and set a $471.00 price objective on shares of argenx in a research report on Friday, March 22nd. Truist Financial increased their price objective on argenx from $370.00 to $440.00 and gave the stock a "buy" rating in a research report on Tuesday, March 5th. Finally, HC Wainwright reiterated a "buy" rating and issued a $451.00 price objective on shares of argenx in a research note on Wednesday. One analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $530.74.
Read Our Latest Report on argenx
argenx Stock Down 1.2 %
Shares of NASDAQ:ARGX traded down $4.87 during midday trading on Thursday, hitting $393.72. The stock had a trading volume of 184,653 shares, compared to its average volume of 349,755. The business's 50-day simple moving average is $387.95 and its 200-day simple moving average is $434.94. argenx has a 12 month low of $327.73 and a 12 month high of $550.76. The company has a market cap of $23.35 billion, a P/E ratio of -76.60 and a beta of 0.65.
argenx (NASDAQ:ARGX - Get Free Report) last announced its earnings results on Thursday, February 29th. The company reported ($1.68) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.45). The business had revenue of $417.84 million for the quarter, compared to analyst estimates of $378.60 million. argenx had a negative return on equity of 16.97% and a negative net margin of 23.26%. During the same quarter in the previous year, the company posted ($0.70) EPS.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Capital World Investors grew its stake in argenx by 37.0% during the fourth quarter. Capital World Investors now owns 1,961,202 shares of the company's stock worth $746,099,000 after purchasing an additional 530,181 shares during the period. Massachusetts Financial Services Co. MA raised its position in shares of argenx by 339.1% during the third quarter. Massachusetts Financial Services Co. MA now owns 581,586 shares of the company's stock worth $285,925,000 after purchasing an additional 449,151 shares during the period. Morgan Stanley grew its position in argenx by 236.9% in the 4th quarter. Morgan Stanley now owns 630,330 shares of the company's stock valued at $238,788,000 after purchasing an additional 443,217 shares during the period. Jennison Associates LLC lifted its stake in shares of argenx by 32.2% in the third quarter. Jennison Associates LLC now owns 1,511,745 shares of the company's stock valued at $743,219,000 after buying an additional 368,367 shares in the last quarter. Finally, Artisan Partners Limited Partnership lifted its position in argenx by 12.2% in the 4th quarter. Artisan Partners Limited Partnership now owns 3,174,477 shares of the company's stock valued at $1,207,666,000 after acquiring an additional 346,178 shares in the last quarter. 60.32% of the stock is owned by institutional investors and hedge funds.
argenx Company Profile
(
Get Free Report)
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, pemphigus foliaceus, chronic inflammatory demyelinating polyneuropathy, bullous pemphigoid, and idiopathic inflammatory myopathy; and ENHANZE SC.
Further Reading
Before you consider argenx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and argenx wasn't on the list.
While argenx currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
